Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SNAC · 2 trials · 2 indications
Based on sampling between 0 and 12 hours
Based on sampling between 0 and 96 hours
PART A
PART B
| Arm | Type | Description |
|---|---|---|
| Furosemide/Rosuvastatin/SNAC/Semaglutide | EXPERIMENTAL | - |
| Part A, SNAC | EXPERIMENTAL | Single dose of 1.2mg, 2.4mg or 3.6mg increasing for each cohort of trial participants. |
| Part A, placebo | PLACEBO_COMPARATOR | Single dose at corresponding dose levels. |
| Part B, SNAC, Placebo, Moxifloxacin | EXPERIMENTAL | Subjects will receive 4 different treatments in random order. SNAC dose between 1.2-3.6 mg, Placebo in two different periods, moxifloxacin 400mg. |
| Name | Type | Description |
|---|---|---|
| Furosemide | DRUG | Oral administration A total of three single doses. |
| Rosuvastatin | DRUG | Oral administration. A total of three single doses. |
| SNAC | DRUG | Oral administration. A total of five single doses. |
| Semaglutide | DRUG | Oral administration. Once daily. |
| Placebo | DRUG | Oral administration |
| Moxifloxacin | DRUG | Oral administration |
Inclusion Criteria: * Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial * Male or female, aged 18-65 years (both inclusive) at the time of ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| FibroBiologics, Inc. | FBLG | 1 | PHASE1 | Undisclosed |
| MiMedx Group, Inc. | MDXG | 2 | N/A | Undisclosed |
| Integra LifeSciences Holdings Corporation | IART | 1 | N/A | Undisclosed |
| Organogenesis Holdings, Inc. Class A | ORGO | 1 | N/A | Undisclosed |
| Healthcare Services Group, Inc. | HCSG | 1 | N/A | Undisclosed |
SNAC is an investigational small molecule being developed by Novo Nordisk A/S for metabolic conditions, studied in healthy volunteers and in diabetes. It is in Phase 1 clinical development and is not approved by the FDA. SNAC is being evaluated for its effects on cardiac repolarization and on the pharmacokinetics of other drugs.
SNAC is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting Phase 1 clinical trials to evaluate the safety and pharmacological effects of SNAC in healthy subjects and in individuals with diabetes.
SNAC is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. Clinical trials are ongoing or completed to assess its safety and how it interacts with other medications, but it is not yet available for clinical use.
SNAC has been studied in two completed Phase 1 trials. NCT02911870 evaluated the effect of SNAC on cardiac repolarization in 84 healthy male subjects in Germany. NCT03010475 investigated the effect of oral semaglutide on the pharmacokinetics of furosemide and rosuvastatin in 41 healthy subjects in the United Kingdom.
SNAC is not the same as oral semaglutide. SNAC is a separate small molecule being studied for its own effects. In one clinical trial, NCT03010475, the effect of oral semaglutide on the pharmacokinetics of other drugs was investigated, and SNAC was part of that study context, but they are distinct compounds.